bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.05.31.494189

Time-lapse Imaging of Microglial Activity and Astrocytic Calcium Signaling Reveals a Neuroprotective Effect of Cannabidiol in the Subacute Phase of Stroke

Abstract

Pharmacological agents that limit secondary tissue loss and/or improve functional outcomes after stroke are still limited. Cannabidiol, the major non-psychoactive component of Cannabis sativa, has been proposed as a neuroprotective agent against experimental focal cerebral ischemia. The effects of cannabidiol have generally been related to the modulation of neuroinflammation, including the control of glial activation and the toxicity exerted by pro-inflammatory mediators. However, so far, most information concerning cannabidiol neuroprotective effects was obtained from histological and biochemical post-mortem assays. To test whether the effects of cannabidiol on glial cells could be also detected in vivo, we performed time-lapse imaging of microglial activity and astrocytic calcium signaling in the subacute phase of stroke using two-photon laser-scanning microscopy. First, C57BL/6N wild-type mice underwent either sham or transient middle cerebral artery occlusion surgery. The animals received intraperitoneal injection of vehicle or cannabidiol (10 mg/kg) 30 min, 24 h, and 48 h after surgery. One day later the neurological score test was performed. Brain tissue was processed to evaluate the neuronal loss and microglial activation. Transgenic mice with microglial expression of the enhanced green fluorescent protein and astrocyte-specific expression of the calcium sensor GCaMP3 were used to access in vivo microglial activity and astrocytic calcium signaling, respectively. The animals were submitted to the same experimental design described above and to imaging sessions before, 30 min, 24 h and, 48 h after surgery. Astrocytic calcium signaling was also assessed in acutely isolated slices 5 h after transient middle cerebral artery occlusion surgery in the presence of perfusion or cannabidiol solution. Cannabidiol prevented ischemia-induced neurological impairments as well as protected against neuronal loss in ischemic mice. Cannabidiol also reduced ischemia-induced microglial activation, as demonstrated in fixed tissue as well in in vivo conditions. No difference in the amplitude and duration of astrocytic calcium signals was detected before and after the middle cerebral artery occlusion in vivo. Similarly, no significant difference was found in the astrocytic calcium signals between contra and ipsilateral side of acutely isolated brain slices. The present results suggest that the neuroprotective effects of cannabidiol after stroke may occur in the subacute phase of ischemia and reinforce the strong anti-inflammatory property of this compound.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Meyer, E., Rieder, P., Gobbo, D., Candido, G., Scheller, A., de Oliveira, R. M. W., Kirchhoff, F.. 2022-06-01. Time-lapse Imaging of Microglial Activity and Astrocytic Calcium Signaling Reveals a Neuroprotective Effect of Cannabidiol in the Subacute Phase of Stroke. https://doi.org/10.1101/2022.05.31.494189

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗